Acetylcysteine lysinate

Drug Profile

Acetylcysteine lysinate

Alternative Names: L-Lysine-N-acetyl-L-cysteinate; N-acetylcysteine lysinate; Nacystelyn

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator Galephar; Laboratoires SMB
  • Class Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 14 Feb 2001 Nacystelyn® has received orphan drug status for cystic fibrosis in the European Union
  • 14 Jun 2000 A study in cystic fibrosis patients has been added to the adverse events and therapeutic trials sections
  • 05 Feb 1998 Phase-III clinical trials for Cystic fibrosis in European Union (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top